…
Axe Compute Inc., a knowledge and science-driven company, applies artificial intelligence (AI) to support the discovery and development of cancer therapies. It operates through two segments, Pittsburgh and Eagan. The Pittsburgh segment provides services that include the application of AI using its proprietary biobank of 150,000+ tumor samples. This segment also creates proprietary 3D culture models used in drug development. Its Eagan segment produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. Predictive Oncology Inc. has a strategic collaboration with Every Cure to identify and prioritize drugs for repurposing. The company was formerly known as Predictive Oncology Inc. and changed its name to Axe Compute Inc. in December 2025. Axe Compute Inc. was incorporated in 2002 and is headquartered in Pittsburgh, Pennsylvania.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Public information on Axe Compute Inc. (AGPU.US) is limited; filings do not provide a clear, verifiable description of the company's core products, customers or financial track record. Consequently long‑term growth drivers are undocumented and investors should consult SEC filings and company reports. The equity may appeal only to those prepared to monitor disclosure, revenue progress and execution closely.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -232.85M | -10.86M | -12.02M | -25.74M | -20.32M |
| Net income | -233.10M | -12.20M | -13.98M | -25.74M | -19.66M |
| Selling general administrative | 25.92M | 7.42M | 7.57M | 11.11M | 10.93M |
| Selling and marketing expenses | 0.41M | 1.47M | 1.49M | 1.36M | 0.77M |
| Gross profit | 0.05M | 0.80M | 1.02M | 1.00M | 0.93M |
| Reconciled depreciation | 0.69M | 0.70M | 0.72M | 1.31M | 1.34M |
| Ebit | -28.43M | -10.94M | -12.12M | -15.27M | -13.47M |
| Ebitda | -27.74M | -10.24M | -11.87M | -13.95M | -12.13M |
| Depreciation and amortization | 0.69M | 0.70M | 0.24M | 1.31M | 1.34M |
| Operating income | -28.43M | -10.94M | -12.12M | -26.03M | -20.43M |
| Other operating expenses | 28.55M | 12.56M | 13.75M | 27.54M | 21.85M |
| Interest expense | - | - | - | 10.65M | - |
| Tax provision | - | - | - | 0.00M | -0.66M |
| Income tax expense | - | - | - | - | -0.66M |
| Total revenue | 0.13M | 1.62M | 1.63M | 1.51M | 1.42M |
| Total operating expenses | 28.48M | 11.74M | 13.14M | 27.03M | 21.36M |
| Cost of revenue | 0.07M | 0.83M | 0.61M | 0.51M | 0.49M |
| Total other income expense net | -204.43M | 0.08M | 0.10M | 0.30M | 0.11M |
| Net income from continuing ops | -232.85M | -10.86M | -12.02M | -25.74M | -19.66M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 52.89M | 4.97M | 14.42M | 25.73M | 43.77M |
| Intangible assets | - | 0.21M | 0.25M | 0.25M | 3.96M |
| Other current assets | 31.95M | 0.36M | 0.59M | 0.53M | 0.51M |
| Total liab | 5.17M | 5.18M | 6.15M | 3.97M | 3.51M |
| Total stockholder equity | 47.72M | -0.20M | 8.27M | 21.77M | 40.27M |
| Other current liab | 1.66M | 1.57M | 1.72M | 2.24M | 1.39M |
| Common stock | 0.04M | 0.07M | 0.04M | 0.04M | 0.66M |
| Capital stock | 0.04M | 0.07M | 0.04M | 0.04M | 0.66M |
| Retained earnings | -413.52M | -180.43M | -167.76M | -153.78M | -128.04M |
| Good will | - | - | - | 0.00M | 6.86M |
| Other assets | - | - | - | - | 0.00M |
| Cash | 10.79M | 0.73M | 8.73M | 22.07M | 28.20M |
| Total current liabilities | 4.27M | 3.59M | 3.95M | 3.88M | 3.24M |
| Current deferred revenue | - | 0.30M | 0.30M | 0.60M | 0.19M |
| Net debt | -9.12M | 1.40M | -6.00M | -21.89M | -27.32M |
| Short term debt | 0.76M | 0.57M | 0.60M | 0.09M | 0.64M |
| Short long term debt | 0.11M | - | 0.15M | - | - |
| Short long term debt total | 1.67M | 2.13M | 2.73M | 0.18M | 0.88M |
| Other stockholder equity | 461.20M | 180.16M | 175.99M | 175.50M | 167.65M |
| Total current assets | 42.77M | 2.23M | 10.08M | 23.36M | 29.46M |
| Net receivables | 0.03M | 0.75M | 0.28M | 0.33M | 0.35M |
| Inventory | - | 0.39M | 0.48M | 0.43M | 0.39M |
| Accounts payable | 1.84M | 1.14M | 1.33M | 0.94M | 1.02M |
| Non currrent assets other | 8.41M | 0.10M | 0.12M | 0.08M | 0.17M |
| Non current assets total | 10.12M | 2.75M | 4.34M | 2.37M | 14.31M |
| Capital lease obligations | 1.56M | 2.13M | 2.58M | 0.18M | 0.88M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total cashflows from investing activities | -31.99M | 0.02M | -0.30M | -0.48M | -10.61M |
| Net borrowings | 0.11M | -0.15M | 0.15M | 0.00M | -4.16M |
| Total cash from financing activities | 52.01M | 3.94M | 0.15M | 6.72M | 50.34M |
| Net income | -233.10M | -10.86M | -12.02M | -25.74M | -19.66M |
| Change in cash | 10.06M | -7.99M | -13.34M | -6.13M | 27.52M |
| Begin period cash flow | 0.73M | 8.73M | 22.07M | 28.20M | 0.68M |
| End period cash flow | 10.79M | 0.73M | 8.73M | 22.07M | 28.20M |
| Total cash from operating activities | -9.96M | -11.96M | -13.19M | -12.37M | -12.21M |
| Issuance of capital stock | 56.01M | 4.96M | 0.00M | 6.74M | 51.20M |
| Depreciation | 0.69M | 0.70M | 0.72M | 1.31M | 1.34M |
| Other cashflows from investing activities | -62.35M | 0.03M | -0.25M | - | -0.06M |
| Dividends paid | - | - | 0.00M | - | - |
| Change to inventory | - | 0.10M | -0.07M | -0.04M | -0.10M |
| Change to account receivables | 0.00M | -0.47M | 0.02M | 0.02M | -0.02M |
| Sale purchase of stock | - | 0.00M | -0.00M | -0.03M | -0.01M |
| Other cashflows from financing activities | -4.11M | - | 0.00M | - | 4.39M |
| Capital expenditures | 32.62M | 0.01M | 0.02M | 0.48M | 0.96M |
| Change in working capital | 1.16M | -0.91M | -0.78M | 0.87M | -1.19M |
| Stock based compensation | - | - | - | 0.52M | 0.92M |
| Other non cash items | 221.29M | -0.88M | -1.12M | 11.19M | 7.04M |
| Free cash flow | -42.49M | -11.97M | -13.21M | -12.85M | -13.17M |
Sector: Technology Industry: Software - Infrastructure
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| AGPU Axe Compute Inc. |
1.20 15.71% |
8.84 | - | - | 204.27 | 0.54 | 131.44 | -0.51 |
| MSFT Microsoft Corporation |
-12.04 2.26% |
521.12 | 37.32 | 29.94 | 13.03 | 12.45 | 13.06 | 24.59 |
| ORCL Oracle Corporation |
10.40 8.82% |
128.38 | 21.96 | 17.89 | 5.91 | 7.08 | 7.82 | 14.89 |
| CRWD Crowdstrike Holdings Inc |
3.30 1.46% |
229.06 | 4849.80 | 188.68 | 46.01 | 47.24 | 43.89 | 559.34 |
| FTNT Fortinet Inc |
4.55 3.68% |
128.12 | 60.27 | 43.86 | 16.80 | 80.50 | 16.11 | 43.33 |
Axe Compute Inc., a knowledge and science-driven company, applies artificial intelligence (AI) to support the discovery and development of cancer therapies. It operates through two segments, Pittsburgh and Eagan. The Pittsburgh segment provides services that include the application of AI using its proprietary biobank of 150,000+ tumor samples. This segment also creates proprietary 3D culture models used in drug development. Its Eagan segment produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. Predictive Oncology Inc. has a strategic collaboration with Every Cure to identify and prioritize drugs for repurposing. The company was formerly known as Predictive Oncology Inc. and changed its name to Axe Compute Inc. in December 2025. Axe Compute Inc. was incorporated in 2002 and is headquartered in Pittsburgh, Pennsylvania.
| Name | Title | Year Born |
|---|---|---|
| Mr. Christopher Miglino | CEO & Director | 1969 |
| Mr. Kyle Okamoto | President | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.